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Abstract
Background: Atrial fibrillation (AF) is associated with increased risk of ischemic 
stroke and all-cause mortality. Patients with AF are also at increased risk of venous 
thromboembolism (VTE), but information on how AF impacts VTE-related mortality 
is scarce.
Objectives: To investigate the impact of AF on all-cause mortality in subjects with 
and without a thromboembolic event (VTE or ischemic stroke).
Methods: We followed 29 833 participants from the Tromsø study (1994-2008) 
through 2013 and recorded all deaths during follow-up. Incident AF, VTE, and ischemic 
stroke were registered as time-dependent exposures. We calculated mortality rates 
(MRs) by exposure during follow-up and obtained hazard ratios (HRs) for death with 
95% confidence intervals (CIs).
Results: A total of 2087 AF cases, 756 VTEs, and 1279 ischemic strokes were reg-
istered during a median follow-up of 18.7 years, and 4797 people (16.1%) died. The 
age-adjusted MR for participants without any event was 1.19 per 100 person-years 
(PY; 95% CI, 1.15-1.23). Compared to these participants, subjects with the joint 
AF + VTE exposure had a 3.7-fold increased risk of death (HR, 3.67; 95% CI, 2.77-
4.66) in age- and sex-adjusted analyses, similar to the risk observed for VTE alone 
(HR, 3.76; 95% CI, 3.28-4.30). Participants with stroke had a 2.9-fold increased risk of 
death (HR, 2.85; 95% CI, 2.56-3.18), and the risk was further increased in participants 
with both AF and stroke (HR, 4.38; 95% CI, 3.85-4.98).
Conclusions: AF was significantly associated with increased risk of death in partici-
pants with incident stroke. In contrast, concomitant AF was not associated with ex-
cess mortality risk in VTE patients.
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Essentials
• The impact of atrial fibrillation (AF) on venous thromboembolism (VTE) mortality is unclear.
• In total, 29 833 participants from the general population were included.
• The joint exposure of AF and VTE was associated with a death risk similar to that for VTE only.
• AF was associated with increased risk of death subjects with stroke, but not in those with VTE.
1  | INTRODUCTION
Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia of 
clinical significance, and a major contributor to the public health 
burden.1,2 AF independently predicts excess morbidity and in-
creases all-cause mortality rates 2-fold in the general population.1,3 
The most detrimental complication of AF is ischemic stroke, and 
the risk of stroke is up to 5-fold increased in patients with AF.1,4 
Furthermore, stroke patients with AF have increased short- and 
long-term case-fatality rates.5,6 Epidemiologic studies have re-
ported 2-fold higher mortality rates in stroke patients with AF com-
pared to those without.7,8
Venous thromboembolism (VTE), encompassing deep vein 
thrombosis (DVT) and pulmonary embolism (PE), is the third-lead-
ing cause of cardiovascular death after myocardial infarction (MI) 
and ischemic stroke and affects 1 to 3 per 1000 persons annually in 
Western populations.9,10 While the impact of AF on the risk of isch-
emic stroke have been known for decades, recent epidemiologic 
studies have demonstrated that AF also increases the risk of VTE.11-
13 A population-based Taiwanese study reported a 3-fold increased 
risk of VTE in subjects with AF.11 Similarly, Sundbøll et al12 found a 
2.4-fold higher incidence rate for PE in the first year following AF 
diagnosis. In a previous publication from the Tromsø study, the risk 
of VTE, and PE in particular, was significantly higher in subjects 
with incident AF than in those without.13 Further cause-specific 
analyses demonstrated that the excessive PE risk conveyed by AF 
could not be explained by the intermediate development of isch-
emic stroke.4
Despite diagnostic and therapeutic advances during the past 
decades, the all-cause mortality rates after VTE, especially after 
PE, remain substantial.14 Whether AF is a prognosticator in VTE 
has not been extensively studied, even though the 2 conditions 
frequently coexist.15-17 AF upon hospital admittance was associ-
ated with reduced survival after VTE in some studies,18,19 while 
others report no impact on mortality regardless of AF onset.16,20 
A recently published meta-analysis found AF at admission to be 
predictive of in-hospital death in patients with PE in unadjusted 
analyses.21
To what extent AF impacts VTE mortality in the general pop-
ulation is unclear. In the present study, we therefore aimed to in-
vestigate the joint effect of AF and VTE on the risk of all-cause 
mortality. For comparison, we simultaneously assessed the joint 




Participants were recruited from the fourth (1994-1995), fifth 
(2001-2002) and sixth (2007-2008) surveys of the Tromsø study, 
an ongoing population-based cohort study of inhabitants of 
Tromsø, Norway. All inhabitants of Tromsø (Tromsø 4) or parts of 
the population (Tromsø 5 and 6) aged ≥ 25 years were invited to 
participate, and 30 586 persons between 25 and 97 years of age 
attended ≥1 of the surveys. A detailed description of the Tromsø 
study cohort has been published previously.22 We excluded all 
participants who withdrew their consent to medical research after 
the Tromsø study inclusion date (n = 181); participants not offi-
cially registered as residents of Tromsø (n = 23); and those with 
VTE (n = 87), ischemic stroke (n = 215), or AF (n = 247) prior to 
study enrollment. A total of 29 833 participants were included in 
the study, and followed from the inclusion date to December 31, 
2013. Incident cases of AF, VTE, and ischemic stroke, as well as 
deaths among all study participants were registered throughout 
follow-up. The study was approved by the Regional Committee for 
Medical and Health Research Ethics, and all participants gave their 
informed, written consent.
2.2 | Baseline measurements
Information on body mass index (BMI), hypertension, self-reported 
diabetes, smoking, and total cholesterol was obtained on the date 
the participant attended the Tromsø study. Blood pressure meas-
urements were carried out using an automatic device (Dinamap 
Vital Signs Monitor, 1846; Critikon Inc). After 2 minutes of seated 
rest, 3 recordings were taken on the upper right arm at 1-minute 
intervals, and the mean of the last 2 values was used in the anal-
yses. Those with systolic blood pressure ≥140 mm Hg, diastolic 
blood pressure ≥90 mm Hg or currently using antihypertensive 
drugs were classified as having hypertension. Nonfasting blood 
samples were obtained from all study participants, and serum total 
cholesterol was measured as previously detailed.23 Height and 
weight were measured with the participant in light clothing and 
no shoes. BMI was calculated as weight in kilograms divided by 
the height in meters squared (kg/m2). History of diabetes and cur-
rent smoking was obtained from self-administered questionnaires, 
and information on prior MI was obtained from the cardiovascular 
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end point registry of the Tromsø study. Information regarding 
cancer diagnosis, either prior to study inclusion or during follow-
up, was obtained by linkage to the Cancer Registry of Norway. 
Participants with a diagnosis of nonmelanoma skin cancer were 
classified as cancer free.
2.3 | Ascertainment of AF
Incident AF was identified by searching the discharge diagno-
sis registry at the University Hospital of North Norway and the 
Norwegian Cause of Death Registry at the Norwegian Institute of 
Public Health, using the International Classification of Diseases, 
Ninth Revision (ICD-9) codes 427.0-427.99 and Tenth Revision 
(ICD-10) codes I47 and I48. For subjects with a diagnosis of car-
diovascular or cerebrovascular disease, but without a registered ar-
rhythmia diagnosis, paper versions of hospital records (used until 
2001) were manually searched for any mention of AF, and the term 
atrial fibrillation was used for text searches in the electronic records. 
An electrocardiogram documenting AF was a prerequisite for AF 
diagnosis, and all events were adjudicated by an independent end 
point committee. Episodes of transient AF documented only in re-
lation to cardiac surgery or an acute MI were not classified as AF 
events.
2.4 | Ascertainment of VTE
Incident VTE cases were identified by searching the hospital dis-
charge diagnosis registry, the autopsy registry, and the radiology 
procedure registry at the University Hospital of North Norway as 
previously described in detail.24 All hospital care and relevant di-
agnostic radiology in the Tromsø municipality are provided solely 
by this hospital. Trained personnel reviewed the medical record of 
each potential patient with VTE for case validation. A VTE episode 
was verified and recorded as a validated outcome when clinical signs 
and symptoms of VTE were combined with objective confirmation 
tests (compression ultrasonography, venography, spiral computed 
tomography, perfusion–ventilation scan, pulmonary angiography, 
or autopsy) and resulted in treatment initiation. For cases retrieved 
from autopsy records, a VTE event was recorded when the death 
certificate designated VTE as the cause of death or a significant 
condition contributing to death. Participants diagnosed with con-
current PE and DVT were registered as having PE. The VTE events 
were further classified as unprovoked (no provoking factors) or pro-
voked (≥1 provoking factor[s]) based on the presence of provoking 
factors at the time of diagnosis. Immobilization (bed rest ≥ 3 days, 
wheelchair, long-haul travel ≥ 4 hours within 14 days prior to the 
event), major surgery, trauma, or an acute medical condition (acute 
MI, ischemic stroke, or major infectious disease) within 8 weeks 
prior to the event; active cancer; or other potential provoking fac-
tors described by a physician in the medical record (eg, intravascular 
catheter) were considered provoking factors.
2.5 | Ascertainment of ischemic stroke
Information on first-ever ischemic strokes was obtained by linkage to 
the diagnostic registries of the University Hospital of North Norway 
and the Norwegian Cause of Death Registry at The Norwegian 
Institute of Public Health, using the ICD, Eighth Revision (ICD-8) and 
ICD-9 codes 430-438, and ICD-10 codes I60-I69 (cerebrovascular 
diseases). Systematic text searches were also performed in the medi-
cal records for patients with ICD-8 and ICD-9 diagnosis codes 410-
414 and 798-799, and ICD-10 codes I20-I25 and R96, R98 and R99, 
to ensure case completeness. The World Health Organization defini-
tion was used to define ischemic stroke: rapidly developing clinical 
signs of focal or global disturbance of cerebral function, with symp-
toms lasting ≥24 hours or leading to death with no apparent cause 
other than vascular origin.25 Moreover, imaging tests (computed to-
mography or magnetic resonance imaging) or autopsy were required 
in order to exclude intracerebral or subarachnoid hemorrhage. An 
independent end point committee followed a detailed protocol ac-
cording to established diagnostic criteria for case validation.
2.6 | Outcome
Information on deaths was retrieved from the Norwegian Population 
Registry by use of the unique national person identification number.
2.7 | Statistical analyses
We performed statistical analyses using STATA version 15.0 (Stata 
Corporation). Attained age was used as the time scale, defining the 
participant’s age at enrollment as entry time, and the age at the 
time of a censoring event (ie, death, migration, or study end) as exit 
time. We calculated crude mortality rates (MRs) and hazard ratios 
(HRs) for death during follow-up by exposure status during follow-
up (no event, AF only, VTE only, ischemic stroke only, or >1 expo-
sure). Poisson regression models were used to obtain age-adjusted 
MRs. All participants contributed with nonexposed person-time 
from the baseline inclusion date to the date of a first event, and 
then with exposed time from that date onward. For participants 
who developed both AF and VTE, AF and ischemic stroke, or VTE 
and ischemic stroke, a third observational period was counted from 
the date of the second diagnosis through the end of follow-up, 
and for those who experienced all 3 events (AF, VTE, and ischemic 
stroke), a fourth observational period was counted from the date 
of the third diagnosis through the end of follow-up (Figure 1). In 
total, 29 833 subjects contributed with 33 899 observational pe-
riods. We further performed stratified analyses by type of VTE 
(PE or DVT), separate analyses of unprovoked and provoked VTEs, 
and analyses in which participants with cancer were censored on 
the date of cancer diagnosis. We tested the assumption of pro-
portional hazards using Schoenfeld residuals and found that the 
“VTE only” and the “AF + VTE” exposures violated the assumption 
     |  1007HALD et AL.
of proportional hazards. We consequently calculated HRs in dif-
ferent age groups (younger vs older participants). Statistical in-
teractions between the different exposures and sex were tested 
by including cross-product terms in the Cox regression models. A 
borderline significant interaction term was found for sex and AF, 
and sex and ischemic stroke, and we further performed analyses 
stratified on sex. The number of participants included in the ad-
justed regression models varied slightly due to missing data for 
some covariates (in total 1.1% missing).
3  | RESULTS
A total of 756 VTE events, 1279 ischemic strokes, and 2087 cases 
of AF were registered during a median of 18.7 years (range, 6 days 
to 19.3 years) of follow-up. The baseline characteristics of those 
who developed incident events (AF, stroke, or VTE) during follow-
up are summarized in Table 1. Participants with any event during 
follow-up were markedly older at inclusion than those without an 
event. Subjects with the joint AF and VTE exposure were on average 
20 years older at inclusion, and those with AF and ischemic stroke 
22 years older, than participants without any event during follow-up 
(Table 1). Furthermore, hypertension, diabetes, and a history of MI 
was more prevalent in those who later developed AF and ischemic 
stroke. Participants with all 3 events (AF, VTE, and ischemic stroke) 
had the highest baseline age, BMI, and cholesterol levels and the larg-
est proportion of hypertension, diabetes, and previous MI (Table 1).
The association between AF, VTE, ischemic stroke, and the joint 
exposures on risk of death is shown in Table 2. During follow-up, 
a total of 4797 persons (16.1%) died. The overall crude mortality 
rates were similar for subjects with AF only (MR, 7.58 per 100 PY; 
95% CI, 7.03-8.19) and VTE only (MR 7.74 per 100 PY; 95% CI, 6.81-
8.81), while the crude MR was considerably higher in participants 
with the joint exposure AF + VTE (16.8 per 100 PY; 95% CI, 13.3-
21.3) (Table 2). After age adjustment, the differences in MRs were 
markedly attenuated, with similar MRs observed for VTE only and 
AF + VTE. The latter exposures conferred an almost 4-fold increased 
risk of death compared with subjects with no event during follow-up 
in analysis using age as the time scale and adjusted for sex (Table 2).
Participants with the combined exposure of both AF and isch-
emic stroke during follow-up had a higher age-adjusted all-cause MR 
of 8.21 per 100 PY (95% CI, 7.22-9.20), compared to those with either 
AF only (MR, 4.24 per 100 PY; 95% CI, 3.92-4.56) or ischemic stroke 
only (MR, 4.93 per 100 PY; 95% CI, 4.43-5.43) (Table 2). In age- and 
sex-adjusted analyses, participants with either AF or ischemic stroke 
had a more than doubled risk of death compared to participants 
without either event, while the HR for death was over 4-fold higher 
in subjects with both events (HR, 4.38; 95% CI, 3.85-4.98) (Table 2). 
F I G U R E  1   Examples of exposure time measured in patients during follow-up. The Tromsø Study 1994-2013. Person A: Contributed 
with nonexposed person-time from inclusion, then with “exposed to VTE” person-time from the date of VTE until AF diagnosis, then with 
“exposed to AF + VTE” person-time from that day onward until death. Person B: Nonexposed to any event throughout the study period. 
Person C: Contributed with nonexposed person-time from inclusion, then with “exposed to stroke” person-time from the date of ischemic 
stroke until death. Person D: Contributed with nonexposed person-time from inclusion, with “exposed to VTE” person-time from the date of 
VTE until stroke diagnosis, then with “exposed to VTE + stroke” person-time to AF diagnosis, and then with “exposed to AF + VTE + stroke” 
person-time until end of follow-up. Person E: Contributed with nonexposed person-time from inclusion until AF diagnosis, then with 
“exposed to AF” until end of follow-up. Person F: Contributed with nonexposed person-time from inclusion, with “exposed to AF” person-




















End of follow up (if still
alive)
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The highest risk of death was observed for subjects with VTE and 
ischemic stroke (HR, 6.32; 95% CI, 4.26-9.37) (Table 2).
In analyses in which participants with a cancer diagnosis prior 
to inclusion (n = 839) were excluded, and those diagnosed with 
cancer during follow-up (n = 2938) were censored at the time of 
cancer diagnosis, the risk estimates for death by VTE were mark-
edly attenuated. In these analyses, the age-adjusted MR was half 
of that observed in the total study population (3.77 per 100 PY; 
95% CI, 3.07-4.47), and the HR of death reduced to 2.05 (95% 
CI, 1.70-2.49). In contrast, risk estimates in cancer-free subjects 
having incident stroke during follow-up were virtually unchanged 
(Table 3). In analyses stratifying the VTE events by unprovoked and 
provoked events, HRs for death were also considerably lower in 
subjects with unprovoked VTE only than for those with provoked 
VTE only (HR, 1.58; 95% CI, 1.22-2.04 versus 6.60; 95% CI, 5.65-
7.70 [data not shown]). For the joint AF + VTE exposure, HRs for 
death were 2.12 (95% CI, 1.42-3.18) and 5.31 (95% CI, 3.97-7.14) 
for unprovoked and provoked VTEs, respectively (data not shown).
When analyzing PE and DVT events separately, both events were 
associated with higher HRs for death compared to AF alone in age- (as 
time scale) and sex-adjusted analyses (Table 4). HRs for death were 
similar in patients with PE (HR, 3.65; 95% CI, 2.51-3.31) and patients 
with DVT (HR, 3.76; 95% CI, 3.19-4.43) compared to participants 
without an event. Further co-occurrence of AF hardly increased the 
risk estimates for either exposure (Table 4). In analyses stratified by 
sex, all HRs were higher in women than in men, but the CIs overlapped 
(Table 5). The VTE only and the AF + VTE exposures violated the as-
sumption of proportional hazards, suggesting a time-dependent ef-
fect of these exposures (ie, age dependency). Both exposures were 
associated with lower absolute risks, but higher relative risks of death 
in younger versus older participants. In persons ≤ 65 years, the age- 
and sex-adjusted HRs for death were 6.26 (95% CI, 5.16-7.60) for the 
VTE only exposure, and 8.54 (95% CI, 5.63-12.96) for the AF + VTE 
exposure, while the comparable HRs in those over 65 years of age 
were 2.84 (95% CI, 2.47-3.19) and 2.90 (95% CI, 2.17-3.90) (data not 
shown).
TA B L E  1   Baseline characteristics of participants (n = 29 833) in persons with and without an exposure status during follow-up
No event













AF + VTE  
+ stroke
(n = 38)
Age, y 45.0 ± 13.6 62.0 ± 12.1 55.7 ± 13.9 61.4 ± 13.1 65.0 ± 10.9 66.9 ± 10.3 65.8 ± 10.4 68.9 ± 8.4
Sex, male 46.4 (12 220) 57.4 (877) 47.9 (267) 58.3 (465) 45.4 (54) 49.1 (198) 46.3 (19) 52.6 (20)
Body mass index, kg/m2 25.1 ± 3.9 26.7 ± 4.1 26.6 ± 4.3 26.1 ± 3.7 27.6 ± 4.2 27.2 ± 4.5 26.7 ± 2.8 28.9 ± 3.8
Hypertension 30.0 (7902) 67.8 (1035) 50.0 (279) 68.1 (543) 64.7 (77) 78.7 (317) 63.3 (26) 81.6 (31)
Total cholesterol, mmol/L 5.88 ± 1.28 6.66 ± 1.23 6.47 ± 1.32 6.71 ± 1.29 6.75 ± 1.17 6.71 ± 1.23 6.85 ± 1.35 7.03 ± 1.06
Smoking 36.5 (9589) 28.7 (436) 33.3 (185) 41.1 (327) 29.4 (35) 23.1 (93) 30.0 (12) 26.3 (10)
Diabetes 1.4 (376) 4.2 (64) 2.0 (11) 4.4 (35) 3.4 (4) 7.0 (28) 7.3 (3) 10.5 (4)
History of myocardial 
infarction
6.3 (1664) 30.0 (458) 11.8 (66) 23.5 (187) 25.2 (30) 37.0 (149) 22.0 (9) 42.1 (16)
Note: Values are given as percentages with absolute numbers in parentheses or as means with standard deviations. The Tromsø Study 1994-2013.
AF, atrial fibrillation; VTE, venous thromboembolism.
*For participants with >1 event, age at the last event is given. 







MR (95% CI)a  HR (95% CI)b 
None 417 040 3144 0.75 (0.73-0.78) 1.19 (1.15-1.23) Ref
AF only 8715 661 7.58 (7.03-8.19) 4.24 (3.92-4.56) 2.36 (2.16-2.57)
VTE only 2996 232 7.74 (6.81-8.81) 6.61 (5.76-7.47) 3.76 (3.28-4.30)
Ischemic stroke only 4641 374 8.06 (7.28-8.92) 4.93 (4.43-5.43) 2.85 (2.56-3.18)
AF + VTE 416 70 16.8 (13.3-21.3) 7.37 (5.64-9.10) 3.67 (2.77-4.66)
AF + ischemic stroke 1365 264 19.3 (17.1-21.8) 8.21 (7.22-9.20) 4.38 (3.85-4.98)
VTE + ischemic stroke 123 25 20.3 (13.7-30.0) 10.1 (6.13-14.0) 6.32 (4.26-9.37)
AF + VTE + ischemic stroke 106 27 25.4 (17.4-37.1) 8.05 (5.01-11.1) 4.50 (3.07-6.58)
Note: The Tromsø Study 1994-2013.
AF, atrial fibrillation; CI, confidence interval; VTE, venous thromboembolism.
aPer 100 person-years. 
bAge as time scale and adjusted for sex. 
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4 | DISCUSSION
In this cohort study, we found that incident AF without concurrent 
VTE or ischemic stroke during follow-up doubled the risk of all-
cause mortality. VTE alone was associated with a 4-fold increased 
risk of death, and was similar to the risk found for AF in combination 
with ischemic stroke. In patients with VTE, concurrent presence of 
AF did not further increase the risk estimates for death.
The increase in absolute and relative risks of death by AF ob-
served in our study is in agreement with previous reports.1,3,26-28 
While the excess mortality may be attributable to heart failure, ei-
ther as a cause or a consequence of AF,27 others have reported that 








MR (95% CI)a  HR (95% CI)b 
None 395 928 3131 0.79 (0.76-0.82) 1.26 (1.21-1.31) Ref
AF only 7337 516 7.03 (6.45-7.68) 3.75 (3.43-4.08) 2.00 (1.82-2.21)
VTE only 2450 111 4.53 (3.76-5.46) 3.77 (3.07-4.47) 2.05 (1.70-2.49)
Ischemic stroke only 4045 313 7.74 (6.93-8.64) 4.62 (4.11-5.14) 2.54 (2.26-2.87)
AF + VTE 308 43 14.0 (10.4-18.8) 5.10 (3.58-6.63) 2.50 (1.84-3.40)
AF + ischemic stroke 1096 216 19.7 (17.2-22.5) 7.95 (6.89-9.02) 4.01 (3.48-4.62)
VTE + ischemic stroke 89 16 17.9 (11.0-29.2) 8.06 (4.11-12.0) 4.34 (2.65-7.11)
AF + VTE + ischemic stroke 80 23 28.9 (19.2-43.5) 7.53 (4.45-10.6) 4.27 (2.82-6.44)
Note: The Tromsø Study 1994-2013.
AF, atrial fibrillation; CI, confidence interval; VTE, venous thromboembolism.
aPer 100 person-years. 




Crude MR (95% 
CI)a  HR (95% CI)b 
None 417 040 3144 0.75 (0.73-0.78) Ref
AF only 8715 661 7.58 (7.03-8.19) 2.31 (2.12-2.52)
PE onlyc  1090 80 7.34 (5.90-9.14) 3.65 (2.51-3.31)
Ischemic stroke only 4641 374 8.06 (7.28-8.92) 2.81 (2.51-3.13)
AF + PEc  199 35 17.6 (12.7-24.5) 3.68 (2.62-5–15)
AF + ischemic stroke 1365 264 19.3 (17.1-21.8) 4.27 (3.75-4.86)
PE + ischemic strokec  29 8 27.6 (13.8-55.2) 6.03 (3.01-12.1)
AF + PE + ischemic 
strokec 
56 15 26.8 (16.1-44.4) 4.09 (2.46-6.80)
None 417 040 3144 0.75 (0.73-0.78) Ref
AF only 8715 661 7.58 (7.03-8.19) 2.33 (2.14-2.54)
DVT onlyd  1906 152 7.97 (6.80-9.35) 3.76 (3.19-4.43)
Ischemic stroke only 4641 374 8.06 (7.28-8.92) 2.82 (2.53-3.16)
AF + DVTd  217 35 16.1 (11.6-22.4) 3.50 (2.51-4.90)
AF + ischemic stroke 1365 264 19.3 (17.1-21.8) 4.31 (3.79-4.91)
DVT + ischemic stroked  94 17 18.0 (11.2-29.0) 6.37 (3.96-10.3)
AF + DVT + ischemic 
stroked 
50 12 23.9 (13.6-42.1) 4.78 (2.71-8.44)
Note: PE and DVT events are analyzed separately. The Tromsø Study 1994-2013.
AF, atrial fibrillation; CI, confidence interval; DVT, deep vein thrombosis; PE, pulmonary embolism; 
VTE, venous thromboembolism.
aPer 100 person-years. 
bAge as time scale and adjusted for sex. 
cParticipants with DVT only censored at the date of the DVT event. 
dParticipants with PE only censored at the date of the PE event. 
TA B L E  4   All-cause mortality rates 
(MRs) and hazard ratios (HRs) for death 
according to exposure categories during 
follow-up
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mortality rates remained elevated in patients with AF after adjust-
ment for MI, congestive heart failure, and valvular heart disease.3 
In a large registry-based study with over 270 000 participants, AF 
was independently associated with all-cause mortality, with higher 
relative risks for death observed for women across all age groups. 
Among concomitant diseases, malignancy, chronic renal failure, and 
chronic obstructive pulmonary disease contributed most to the ex-
cess mortality in AF patients.28
The role of concurrent AF as a prognosticator in patients with 
VTE has not been extensively studied. The majority of studies to 
date have investigated AF in the setting of hospitalization for PE 
and its impact on short-term case fatality.15,18,19,29 In a retrospec-
tive study involving 270 patients with acute PE, a history of AF 
was associated with increased intrahospital 1-month and 6-month 
death rates independent of age.15 Similarly, Geibel and cowork-
ers found atrial arrhythmias to be associated with increased 30-
day mortality in patients admitted with major PE.18 In the present 
study, we found that VTE alone was associated with an overall 
4-fold increased risk of death, which is similar to the risk reported 
in the Multiple Environment and Genetic Assessment (MEGA) 
study.30 The coexistence of AF did not contribute with additional 
risk. A plausible explanation for our findings is that patients with 
VTE in part die as a result of other comorbidities, and that VTE 
patients with AF are compared to VTE patients with high morbid-
ity risk due to other causes, for instance, cancer. This hypothesis 
is supported by the observation that the risk estimates for death 
by VTE were significantly higher in participants with a provoked 
VTE event than in those with an unprovoked event, and corre-
spondingly attenuated when cancer patients were censored upon 
cancer diagnosis.
In agreement with previous reports,5,31 we observed an in-
creased all-cause mortality by AF in patients with ischemic stroke. 
Several mechanisms may explain this finding. Cardiac emboli sec-
ondary to AF are typically larger than the platelet rich-thrombi seen 
in atherosclerotic disease and may occlude larger vessels, resulting in 
more severe strokes. Furthermore, larger infarction volumes, higher 
rates of hemorrhagic transformation and cardiac hypoperfusion in 
patients with AF contributes to increased stroke severity. More se-
vere strokes may in turn result in prolonged immobilization, med-
ical complications, worsened neurological outcome, and increased 
mortality.5
The main strengths of our study include the prospective de-
sign, participant recruitment from a general population, and a 
thorough validation of the exposure events. Information on cancer 
was available, allowing for an assessment of the impact of a cancer 
diagnosis on mortality rates. Confirming the established associa-
tion between AF and ischemic stroke on all-cause mortality in the 
present study population serves to confirm proper classification 
of the exposure measures. Nevertheless, our study also has lim-
itations that merit attention. The AF incidence in our study popu-
lation may be an underestimation, as AF is asymptomatic in many 
cases. Furthermore, patients with AF treated only by their general 
practitioners are not included. The omission of patients with AF 
treated solely in general practice may potentially cause selection 
bias, as more severe cases of AF are more likely to require hospital 
treatment. Due to the observational nature of the study design, 
our study is vulnerable to unmeasured or residual confounding. 
The higher prevalence of cardiovascular risk factors among people 
who developed ≥1 exposure events may have resulted in higher 
heart failure and MI rates among these participants, contributing 
to excess mortality. Unfortunately, we did not have information on 
heart failure, stroke sequelae, hospitalizations, or medication use 
during follow-up. Further knowledge of comorbidities may have 
added to the etiologic understanding of our findings. Information 
on antithrombotic medication use was not available. As anti-
thrombotic treatment, either with antiplatelet agents (for ischemic 
stroke) or with anticoagulants (for all 3 exposures), is the mainstay 
of therapy for both AF, VTE, and ischemic stroke, it is possible 
that we underestimate the true risk of death by these exposures in 
the population. Caution is warranted when interpreting the results 




years Deaths HR (95% CI)a  Person-years Deaths HR (95% CI)a 
None 223 976 1531 Ref 193 065 1613 Ref
AF only 3657 312 2.51 (2.21-2.85) 5058 349 2.21 (1.96-2.49)
VTE only 1561 127 4.17 (3.47-5.01) 1435 105 3.35 (2.74-4.08)
Ischemic stroke only 1838 169 3.26 (2.78-3.84) 2803 205 2.56 (2.21-2.98)
AF + VTE 219 44 3.88 (2.85-5.27) 196 26 3.47 (2.35-5.13)
AF + ischemic stroke 652 143 5.01 (4.26-6.07) 713 121 3.73 (3.09-4.51)
VTE + ischemic stroke 49 13 8.05 (4.65-13.9) 74 12 5.10 (2.89-9.02)
AF + VTE + ischemic stroke 57 15 4.62 (2.77-7.72) 49 12 4.40 (2.49-7.80)
Note: The Tromsø Study 1994-2013.
AF, atrial fibrillation; CI, confidence interval; VTE, venous thromboembolism.
aAge as time scale. 
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of subgroups in which there are low numbers of the exposure(s) 
and outcome(s) of interest. In analyses investigating the joint ex-
posures of AF and VTE, or AF and ischemic stroke, we did not take 
the temporal sequence of events into consideration. However, a 
bidirectional association exists between AF and VTE,4,13,32 and 
although AF is an established risk factor for ischemic stroke, the 
diagnosis is made after the incident stroke in a significant num-
ber of cases.33 Knowledge of the latter may introduce surveillance 
bias, as patients with idiopathic ischemic stroke are monitored for 
potential AF after the incident event. For the scope of the present 
analysis, we assumed that the temporality of events for the joint 
outcomes would be of little importance.
In conclusion, the present study confirms the aggravated risk of 
death by AF in the general population. While concurrent AF is asso-
ciated with a worse prognosis in subjects with ischemic stroke, the 
high relative mortality risk in VTE patients is not further increased 
by the presence of AF.
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